Issue 27, 2014

The development of chitosan based microcapsules as delivery vehicles for orally administered daunorubicin

Abstract

This study reports the use of chitosan microcapsules for daunorubicin delivery via an oral route. The potential oral delivery of the daunorubicin/chitosan microcapsules was examined using an in vivo athymic nude mice xenograft model with Non-Hodgkin's lymphoma cells. Microencapsulated daunorubicin could be administered orally with tumour growth inhibition activity.

Graphical abstract: The development of chitosan based microcapsules as delivery vehicles for orally administered daunorubicin

Article information

Article type
Paper
Submitted
09 Jan 2014
Accepted
28 Jan 2014
First published
28 Jan 2014

RSC Adv., 2014,4, 14109-14114

The development of chitosan based microcapsules as delivery vehicles for orally administered daunorubicin

P.-L. Lam, K. K.-H. Lee, Y.-W. Ho, R. S.-M. Wong, S.-W. Tong, C.-H. Cheng, K.-H. Lam, J. C.-O. Tang, Z.-X. Bian, R. Gambari, S. H.-L. Kok and C.-H. Chui, RSC Adv., 2014, 4, 14109 DOI: 10.1039/C4RA00195H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements